Singapore markets open in 1 hour 42 minutes

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.62-0.02 (-0.14%)
At close: 04:00PM EST
14.75 +0.13 (+0.89%)
After hours: 07:53PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 46.22B
Enterprise value 75.10B
Trailing P/E 39.09
Forward P/E 24.81
PEG Ratio (5 yr expected) 3.48
Price/sales (ttm)1.67
Price/book (mrq)1.02
Enterprise value/revenue 0.02
Enterprise value/EBITDA 0.07

Trading information

Stock price history

Beta (5Y monthly) 0.54
52-week change 3-5.00%
S&P500 52-week change 327.79%
52-week high 317.15
52-week low 313.19
50-day moving average 314.43
200-day moving average 315.03

Share statistics

Avg vol (3-month) 31.94M
Avg vol (10-day) 31.92M
Shares outstanding 53.14B
Implied shares outstanding 63.16B
Float 81.55B
% held by insiders 10.00%
% held by institutions 12.64%
Shares short (31 Jan 2024) 48.54M
Short ratio (31 Jan 2024) 44.19
Short % of float (31 Jan 2024) 4N/A
Short % of shares outstanding (31 Jan 2024) 40.24%
Shares short (prior month 29 Dec 2023) 47.88M

Dividends & splits

Forward annual dividend rate 40.64
Forward annual dividend yield 44.36%
Trailing annual dividend rate 3184.00
Trailing annual dividend yield 31,256.83%
5-year average dividend yield 44.71
Payout ratio 4158.21%
Dividend date 311 Dec 2023
Ex-dividend date 428 Sept 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 4.28%
Operating margin (ttm)9.44%

Management effectiveness

Return on assets (ttm)2.61%
Return on equity (ttm)2.76%

Income statement

Revenue (ttm)4.17T
Revenue per share (ttm)1,335.47
Quarterly revenue growth (yoy)1.30%
Gross profit (ttm)N/A
EBITDA 1.21T
Net income avi to common (ttm)178.22B
Diluted EPS (ttm)0.37
Quarterly earnings growth (yoy)-11.30%

Balance sheet

Total cash (mrq)288.36B
Total cash per share (mrq)183.79
Total debt (mrq)5.21T
Total debt/equity (mrq)77.21%
Current ratio (mrq)1.06
Book value per share (mrq)4,297.21

Cash flow statement

Operating cash flow (ttm)731.45B
Levered free cash flow (ttm)-9.88B